Experimental research on ectopic osteogenesis of BMP2-derived peptide P24 combined with PLGA copolymers

Abstract

To experimentally evaluate the ectopic osteogenetic capacity of synthesized BMP2-derived peptide P24 combined with poly lactic-co-glycolic acid (PLGA), Wistar rats were divided into two groups: group A, in which BMP2-derived peptide P24/PLGA complex was implanted, and group B which received simple PLGA implant. The complex was respectively implanted into the back muscles of rats. Samples were taken the 1st, 4th, 8th, and the 12th week after the implantation. Their bone formation was detected by X-ray examination, and tissue response was histologically observed. Western blotting was used for the detection of the expression of collagen I (Col-I) and osteopontin (OPN). There was acute inflammation in the tissue around both types of implants at early stage. The cartilage was found around implant areas 4 weeks after the implantation of BMP2-derived peptide p24/PLGA complex, 8 weeks after the implantation, osteoblasts were found, and 12 weeks after the implantation, typical trabecular bone structure was observed. In group B, after 12 weeks, no osteoblasts were found. It is concluded that PLGA is an ideal scaffold material for bone tissue engineering. BMP2-derived peptide can start endochondral ossification and is more effective in inducing ectopic osteogenesis.

Keywords

BMP2-derived peptide P24 / PLGA / ectopic osteogenesis

References

[1] RenT., RenJ., JiaX., et al.. The bone formation in vitro and mandibular defect repair using PLGA porous scaffolds. J Biomed Mater Res A, 2005, 74(4): 562-569

[2] DayR. M., BoccacciniA. R., MaquetV., et al.. In vivo characterization of a novel bioresorbable poly (lactide-co-glycolide) tubular foam scaffold for tissue engineering applications. J Mater Sci Mater Med, 2004, 15(6): 729-734

[3] KimC. S., KimJ. I., KimJ., et al.. Ectopic bone formation associated with recombinant human bone morphogenetic proteins-2 using absorbable collagen sponge and beta tricalcium phosphate as carriers. Biomaterials, 2005, 26(15): 2501-2507

[4] GratzerP. F., LeeJ. M.. Control of pH alters the type of cross-linking produced by 1-Ethyl-3-(3-dimethy laminopropyl)-carbodiimide (EDC): Treatment of acellular matrix vascular grafts. J Biomed Mater Res, 2001, 58(2): 172-179

[5] WozneyJ., SeehermanH.. Protein-based tissue engineering in bone and cartilage repair. Curr Opin Biotechnol, 2004, 15(5): 392-398

[6] SaitoN., TakaokaK.. New synthetic biodegradable polymers as BMP carriers for bone tissue engineering. Biomaterials, 2003, 24(13): 2287-2293

[7] ChadderdonR., ShimerA., GilbertsonL. G.. Advances in gene therapy for intervertebral disc degeneration. Spine, 2004, 4(6Suppl): 341S-347S

[8] KirschT., SebaldW., DreyerM. K.. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol, 2000, 7(6): 492-496

[9] GeigerM., LiR. H., FriessW.. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev, 2003, 55(12): 1613-1629

[10] TsumakiN., YoshikawaH.. The role of bone morphogenetic proteins in endochondral bone formation. Cytokine and Growth Factor Reviews, 2005, 16(3): 279-285

[11] KugimiyaF., KawaguchiH., ChungU. I.. BMP and bone formation. Clin Calcium, 2004, 14(1): 173-179

[12] KirschT., NickelJ., SebaldW.. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor. BMPRII. EMBO J, 2000, 19(13): 3314-3324

[13] KirschT., SebaldW., DreyeM. K.. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct. Biol, 2000, 7(6): 492-496